Warning! GuruFocus detected
1 Severe warning sign
with AKRO.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Akero Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US00973Y1082
Compare
Compare
Traded in other countries / regions
AKRO.USA0K4.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2019-06-20Description
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 20.38 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.15 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -8.4 | |||||
| 3-Year EPS without NRI Growth Rate | -9.1 | |||||
| 3-Year FCF Growth Rate | -14.6 | |||||
| 3-Year Book Growth Rate | 28.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -8.65 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.54 | |||||
| 9-Day RSI | 37.27 | |||||
| 14-Day RSI | 40.05 | |||||
| 3-1 Month Momentum % | 61.26 | |||||
| 6-1 Month Momentum % | 64.7 | |||||
| 12-1 Month Momentum % | 96.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 19.38 | |||||
| Quick Ratio | 19.38 | |||||
| Cash Ratio | 18.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -27.5 | |||||
| Shareholder Yield % | -13.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -34.36 | |||||
| ROA % | -31.5 | |||||
| ROIC % | -566.97 | |||||
| 3-Year ROIIC % | -338.09 | |||||
| ROC (Joel Greenblatt) % | -27616.88 | |||||
| ROCE % | -32.23 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.7 | |||||
| Price-to-Tangible-Book | 3.7 | |||||
| EV-to-EBIT | -9.91 | |||||
| EV-to-Forward-EBIT | -7.02 | |||||
| EV-to-EBITDA | -9.91 | |||||
| EV-to-Forward-EBITDA | -7.16 | |||||
| EV-to-FCF | -11.44 | |||||
| Price-to-Net-Current-Asset-Value | 4.03 | |||||
| Price-to-Net-Cash | 4.2 | |||||
| Earnings Yield (Greenblatt) % | -10.09 | |||||
| FCF Yield % | -7.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AKRO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Akero Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.75 | ||
| Beta | -0.44 | ||
| 3-Year Sharpe Ratio | 0.75 | ||
| 3-Year Sortino Ratio | 1.94 | ||
| Volatility % | 105.83 | ||
| 14-Day RSI | 40.05 | ||
| 14-Day ATR ($) | 2.494527 | ||
| 20-Day SMA ($) | 43.3235 | ||
| 12-1 Month Momentum % | 96.46 | ||
| 52-Week Range ($) | 17.86 - 58.4 | ||
| Shares Outstanding (Mil) | 79.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Akero Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Akero Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Akero Therapeutics Inc Frequently Asked Questions
What is Akero Therapeutics Inc(AKRO)'s stock price today?
The current price of AKRO is $38.38. The 52 week high of AKRO is $58.40 and 52 week low is $17.86.
When is next earnings date of Akero Therapeutics Inc(AKRO)?
The next earnings date of Akero Therapeutics Inc(AKRO) is 2025-05-09 Est..
Does Akero Therapeutics Inc(AKRO) pay dividends? If so, how much?
Akero Therapeutics Inc(AKRO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers